Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
Ssharfaei (talk | contribs)
Ssharfaei (talk | contribs)
Line 537: Line 537:
|-
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rheumatologic/autoimmune disorders
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rheumatologic/autoimmune disorders
! align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia
! colspan="2" align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia
!
|Antibody-mediated platelet destruction
|Antibody-mediated platelet destruction
|
|
Line 568: Line 567:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Systemic lupus erythematosus (SLE)
! colspan="2" align="center" style="background:#DCDCDC;" + |Systemic lupus erythematosus (SLE)
!
|
!
|
|
|
|
Line 599: Line 597:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Antiphospholipid syndrome (APS)
! colspan="2" align="center" style="background:#DCDCDC;" + |Antiphospholipid syndrome (APS)
!
|autoantibody-mediated syndrome
!autoantibody-mediated syndrome
!
!
!
!
Line 630: Line 627:
!
!
|-
|-
! align="center" style="background:#DCDCDC;" + |Felty's syndrome
! colspan="2" align="center" style="background:#DCDCDC;" + |Felty's syndrome
!
!splenomegaly
!splenomegaly
!
!
Line 952: Line 948:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Heparin-induced thrombocytopenia
! colspan="2" align="center" style="background:#DCDCDC;" + |Heparin-induced thrombocytopenia
!
|
|
|
|
Line 983: Line 978:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy
! colspan="2" align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy
!
|
|
| +
| +
Line 1,014: Line 1,008:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Radiation therapy
! colspan="2" align="center" style="background:#DCDCDC;" + |Radiation therapy
!
|Predictable, dose-dependent myelosuppression
|Predictable, dose-dependent myelosuppression
| +
| +
Line 1,077: Line 1,070:
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI
! align="center" style="background:#DCDCDC;" + |Chronic liver disease
! colspan="2" align="center" style="background:#DCDCDC;" + |Chronic liver disease
!
|
|
| +
| +
Line 1,108: Line 1,100:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Portal hypertension
! colspan="2" align="center" style="background:#DCDCDC;" + |Portal hypertension
!
|
|
|
|
Line 1,172: Line 1,163:
|-
|-
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vascular  
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vascular  
! align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma  
! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma  
!
!platelet destruction  
!platelet destruction  
!
!
Line 1,203: Line 1,193:
!
!
|-
|-
! align="center" style="background:#DCDCDC;" + |Aortic aneurysm  
! colspan="2" align="center" style="background:#DCDCDC;" + |Aortic aneurysm  
!
!platelet destruction  
!platelet destruction  
!
!
Line 1,234: Line 1,223:
!
!
|-
|-
! align="center" style="background:#DCDCDC;" + |Cardiopulmonary bypass
! colspan="2" align="center" style="background:#DCDCDC;" + |Cardiopulmonary bypass
!
!platelet destruction  
!platelet destruction  
!
!
Line 1,266: Line 1,254:
|-
|-
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! align="center" style="background:#DCDCDC;" + |Alcohol
! colspan="2" align="center" style="background:#DCDCDC;" + |Alcohol
!
!
!
!+
!+
Line 1,297: Line 1,284:
!
!
|-
|-
! align="center" style="background:#DCDCDC;" + |Post-transfusion purpura
! colspan="2" align="center" style="background:#DCDCDC;" + |Post-transfusion purpura
!
!immune-mediated platelet destruction
!immune-mediated platelet destruction
!
!
Line 1,328: Line 1,314:
!
!
|-
|-
! align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia
! colspan="2" align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia
!
!
!
!
!

Revision as of 22:16, 14 August 2018

Thrombocytopenia Differential Diagnosis

Differentiating the diseases that can cause thrombocytopenia:

Category Condition Mechanism Mechanism Inherited Acquried Clinical manifestations Para−clinical findings Gold standard Associated findings
Age range History Symptoms Signs
Lab Findings Imaging
Severity Fever Rash Bleeding BP Splenomegaly Jaundice Other CBC PBS Bone marrow exam PT PTT BT UA
Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Plt HB WBC
Hematology Bone marrow disorders Myelodysplastic syndromes +
Aplastic anemia +
Acute leukemia +
Paroxysmal nocturnal hemoglobinuria (PNH) + Diagnosis of exclusion
Thrombotic microangiopathy (TMA) Thrombotic thrombocytopenic purpura (TTP) +
Hemolytic uremic syndrome (HUS) +
DIC
Congenital platelet disorders MYH-9 related disorders
Bernard-Soulier syndrome
Gray platelet syndrome
Wiskott-Aldrich syndrome
Thrombocytopenia with absent radius (TAR) syndrome
Alport syndrome
Von Willebrand disease
Nutrient deficiencies Folate, vitamin B12, copper an autoimmune mechanism +
Category Condition Mechanism Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Inherited Acquried Age range History Severity Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT BT UA Imaging Gold standard Associated findings
Rheumatologic/autoimmune disorders Immune thrombocytopenia Antibody-mediated platelet destruction + Moderate to severe -
Systemic lupus erythematosus (SLE)
Antiphospholipid syndrome (APS) autoantibody-mediated syndrome
Felty's syndrome splenomegaly
Infection-induced Bacterial infections Sepsis Direct bone marrow suppression + +
Helicobacter pylori Immune thrombocytopenia +
Tick-borne infection +
Viral infections HIV
  • Direct toxicity to megakaryocytes
  • An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
  • Secondary opportunistic infections
+
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus +
Intracellular parasites Malaria
Babesiosis
Category Condition Mechanism Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Inherited Acquried Age range History Severity Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT BT UA Imaging Gold standard Associated findings
Medication/toxicity Drug-induced immune thrombocytopenia
  • Antibiotics
    • Sulfonamides
    • Ampicillin
    • Piperacillin
    • Vancomycin
    • Rifampin
  • Older antiepileptic agents
    • carbamazepine
    • Phenytoin
  • Quinine
Occurrence of drug-dependent, platelet-reactive antibodies +
Heparin-induced thrombocytopenia +
Cytotoxic chemotherapy +
Radiation therapy Predictable, dose-dependent myelosuppression +
OTC agents Quinine-containing beverages
GI Chronic liver disease + Mild
Portal hypertension
Category Condition Mechanism Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Inherited Acquried Age range History Severity Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT BT UA Imaging Gold standard Associated findings
Vascular Giant capillary hemangioma platelet destruction +
Aortic aneurysm platelet destruction +
Cardiopulmonary bypass platelet destruction +
Other Alcohol +
Post-transfusion purpura immune-mediated platelet destruction
Gestational thrombocytopenia +